Recent News

• 09.05.2025 - Cantor Global Healthcare Conference
• 08.21.2025 - Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
• 08.21.2025 - Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
• 08.13.2025 - Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
• 08.13.2025 - Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
• 08.12.2025 - Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
• 08.12.2025 - Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
• 08.07.2025 - T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses
• 07.16.2025 - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
• 07.16.2025 - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Recent Filings

• 08.12.2025 - 8-K Current report
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.01.2025 - 8-K Current report